Bär & Karrer partner Daniel Hochstrasser (pictured) has been nominated for election to the Board of Directors of Novartis, a global healthcare company based in Switzerland, which will take place at the Annual General Meeting on March 4, 2022. Daniel Hochstrasser will leave the Bär & Karrer partnership at the end of 2022 after 29 […]
Tags : Novartis
Novartis announced the appointment of Karen L. Hale (pictured) as Chief Legal Officer. She will report to Vas Narasimhan, M.D., CEO of Novartis and become a member of the Executive Committee of Novartis (ECN), effective May 15, 2021.
She had already worked for Novartis as legal counsel from 2014 to 2017. She joins the company from Amgen where she was associate Legal Counsel Italy & Greece from July 2017 to January 2021. Verdesca also worked as lawyer for over 5 years in Pirola Pennuto Zei & Associati.
Moderna, a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced that Shannon Thyme Klinger (pictured) will join the Company as Chief Legal Officer, effective June 1, 2021.
Novartis announced that Shannon Thyme Klinger (pictured) Chief Legal Officer, has decided to resign from Novartis and return to the US to take an executive role at a biotechnology company. Ms. Klinger will step down from the Executive Committee of Novartis (ECN), effective March 15, 2021.
A cross-border Baker McKenzie team was led by London partner and co-head of the Firm’s renewables group, Marc Fèvre, assisted by Graham Richmond, Saskia Volhard and Lewis Malkin, working with a team in Madrid led by Antonio Morales and Jorge Gomez, and Ansgar Schott (pictured) in Zurich.
The pharma giant’s preferred law firms must make diversity commitments. If they fail them, the Switzerland-based company will withhold 15% of total billings. Legalcommunity.ch talk to the group general counsel about the initiative
The number of deals of at least Usd 10 billion in Europe hit the lowest number since 2009, but two out the top five major deal are in Switzerland.
Bär & Karrer acted as Swiss legal advisor to Novartis in the acquisition of NASDAQ-listed biopharmaceutical company The Medicines Company for USD 9.7 billion
